Author: Jean-Claude Muller, 穆卓Executive Editor at BtoBioInnovation,   jcm@btobioinnovation.com           Editor’s Note   Britain vote to leave the European Union, a historic decision sure to reshape current and future business activities in the biopharmaceutical environment. As a first direct consequence the European Medicines Agency (EMEA), the drug regulator for Europe, which […]

    Author: Jean-Claude Muller, 穆卓Executive Editor at BtoBioInnovation,   jcm@btobioinnovation.com     Zika virus   A World Health Organization (WHO) panel has indicated that there was no need to postpone or move the 2016 Olympic Games in Rio de Janeiro (August 5-21). The Games will take place during the Brazilian winter season when the concentration of […]

        Author: Jean-Claude Muller, 穆卓Executive Editor at BtoBioInnovation,   jcm@btobioinnovation.com   Acquisitions /mergers/joint-ventures   Merck & Co acquires Afferent Pharmaceuticals (San Mateo, CA, USA) in a deal worth up to $1.25 billion, giving access to AF-219, a selective, non-narcotic, orally-administered P2X3 antagonist, currently evaluated for the treatment of refractory, chronic cough, as well as […]

Biopharmaceutical News Week # 2016.22     Author: Jean-Claude Muller, 穆卓Executive Editor at BtoBioInnovation,   jcm@btobioinnovation.com      Zika virus   Physicians at the Hackensack University Medical Center (NJ, USA) have confirmed the birth of the first baby born with Zika-linked microcephaly in the New York area. The mother is said to have contracted Zika while in […]